AR-1001 is under clinical development by AriBio and currently in Phase III for Alzheimer’s Disease. According to GlobalData, Phase III drugs for Alzheimer’s Disease have an 11% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how AR-1001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AR-1001 is under development for the treatment of Alzheimer's disease, vascular dementia, Lewy body dementia, post traumatic stress disorder (PTSD), stroke and amyotrophic lateral sclerosis(ALS). The therapeutic candidate is formulated in tablet form and administered through oral route. The therapeutic candidate acts by targeting phosphodiesterase type 5 (PDE5). It was under development for the treatment of Parkinson's disease.
AriBio Co Ltd is a biopharmaceutical business specialising in the development of novel medications to treat diseases including alzheimer’s, sepsis, and obesity. The company is headquartered in Seongnam-si, Gyeonggi-do, Republic of Korea (South Korea).
For a complete picture of AR-1001’s drug-specific PTSR and LoA scores, buy the report here.